Design, optimization, and multisite evaluation of a targeted next-generation sequencing assay system for chimeric RNAs from gene fusions and exon-skipping events in non –small-cell lung cancer

Lung cancer accounts for approximately 14% of all newly diagnosed cancers and is the leading cause of cancer-related deaths. Chimeric RNA resulting from gene fusions (RNA fusions) and other RNA splicing errors are driver events and clinically addressable targets for non –small-cell lung cancer (NSCLC). The reliable assessment of these RNA markers by next-generation sequencing requires integrated reagents, protocols, and interpretive software that can harmonize procedures and assure consistent results across laboratories.

Source: Journal of Molecular Diagnostics - December 4, 2018 Category: Pathology Authors: Richard A. Blidner, Brian C. Haynes, Stephen Hyter, Sarah Schmitt, Ziyan Y. Pessetto, Andrew K. Godwin, Dan Su, Patrick Hurban, L éon C. van Kempen, Maria L. Aguirre, Shobha Gokul, Robyn D. Cardwell, Gary J. Latham Tags: Regular Article Source Type: research